Exact Mass: 383.2056486

Exact Mass Matches: 383.2056486

Found 90 metabolites which its exact mass value is equals to given mass value 383.2056486, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Anagliptin

N-(2-{[2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl]amino}-2-methylpropyl)-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide

C19H25N7O2 (383.206963)


   

L-Proline, 1-(N-((3-((propylamino)carbonyl)oxiranyl)carbonyl)-L-isoleucyl)-, (2S-trans)-

1-((S)-3-Methyl-2-(((2S,3S)-3-propylcarbamoyl-oxiranecarbonyl)-amino)-pentanoyl)-pyrrolidine-2-carboxylic acid

C18H29N3O6 (383.20562540000003)


   

Losmapimod

6-(5-((cyclopropylamino)Carbonyl)-3-fluoro-2-methylphenyl)-N-(2,2-dimethylprpyl)-3-pyridinecarboxamide

C22H26FN3O2 (383.2008948)


C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2149 - Mitogen-Activated Protein Kinase Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

Propiverine N-oxide

4-[(2,2-diphenyl-2-propoxyacetyl)oxy]-1-methylpiperidin-1-ium-1-olate

C23H29NO4 (383.20964740000005)


   

Tilsuprost

Methyl 4-{[5-hydroxy-4-(3-hydroxyoct-1-en-1-yl)-3H,3ah,4H,5H,6H,6ah-cyclopenta[b]pyrrol-2-yl]sulphanyl}butanoic acid

C20H33NO4S (383.2130178000001)


   
   
   
   

Daphnilongeranin A

methyl (1S,2S,5S)-2,6-dimethyl-21-oxo-14-oxa-8-azahexacyclo[11.6.1.11,5.02,10.03,8.017,20]henicosa-13(20),17-diene-18-carboxylate

C23H29NO4 (383.20964740000005)


   
   
   

LPC 8:0

1-Octanoyl-sn-glycerol-3-phosphorylcholine

C16H34NO7P (383.2072784)


   
   
   
   
   

Spiramide

8-(3-(4-Fluorophenoxy) propyl)-1-phenyl-1,3,8-triazaspiro(4, 5)decan-4-one

C22H26FN3O2 (383.2008948)


Spiramide is an azaspiro compound that consists of 1,3,8-triazaspiro[4.5]decan-4-one having a phenyl group attached to N-1 and a 3-(4-fluorophenoxy)propyl attached to N-8. Selective 5-HT antagonist, which binds to 5-HT2 sites as potently as spiperone but has lower affinity for 5-HT2C receptors. Also a high affinity D2 receptor antagonist (Ki = 3 nM). Lacks the disruptive effect of spiperone on animal behaviour. It has a role as a dopaminergic antagonist and a serotonergic antagonist. It is an azaspiro compound, an organofluorine compound, an aromatic ether, a tertiary amino compound and a member of piperidines. Spiramide is a natural product found in Spiraea japonica with data available. C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent Spiramide (AMI-193) is a potent and selective antagonist of 5-HT2 and dopamine D2 receptor, with Kis of 2 nM and 3 nM, respectively. Spiramide has >2000-fold selectivity for 5-HT2 versus 5-HT1C (Ki=4300 nM) receptors. Spiramide exhibits antipsychotic activity[1][2][3]. Spiramide (AMI-193) is a potent and selective antagonist of 5-HT2 and dopamine D2 receptor, with Kis of 2 nM and 3 nM, respectively. Spiramide has >2000-fold selectivity for 5-HT2 versus 5-HT1C (Ki=4300 nM) receptors. Spiramide exhibits antipsychotic activity[1][2][3]. Spiramide (AMI-193) is a potent and selective antagonist of 5-HT2 and dopamine D2 receptor, with Kis of 2 nM and 3 nM, respectively. Spiramide has >2000-fold selectivity for 5-HT2 versus 5-HT1C (Ki=4300 nM) receptors. Spiramide exhibits antipsychotic activity[1][2][3].

   

18-Aminoabieta-8,11,13-Triene Sulfate

18-Aminoabieta-8,11,13-Triene Sulfate

C20H33NO4S (383.2130178000001)


   

Platelet-activating factor

3,5,9-Trioxa-4-phosphapentadecan-1-aminium, 7-(acetyloxy)-4-hydroxy-N,N,N-trimethyl-, inner salt, 4-oxide, (1)-

C16H34NO7P (383.2072784)


   

1-Octanoyllysolecithin

3,5,9-Trioxa-4-phosphaheptadecan-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide, (R)-

C16H34NO7P (383.2072784)


   

PC(8:0/0:0)[U]

3,5,9-Trioxa-4-phosphaheptadecan-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide

C16H34NO7P (383.2072784)


   

PC(0:0/8:0)[U]

3,5,8-Trioxa-4-phosphahexadecan-1-aminium, 4-hydroxy-7-(hydroxymethyl)-N,N,N-trimethyl-9-oxo-, inner salt, 4-oxide

C16H34NO7P (383.2072784)


   
   

tert-Butyl (3R,4R)-4-(4-benzyloxyphenyl)-3-hydroxypiperidine-1-carboxylate

tert-Butyl (3R,4R)-4-(4-benzyloxyphenyl)-3-hydroxypiperidine-1-carboxylate

C23H29NO4 (383.20964740000005)


   

Trifenagrel

Trifenagrel

C25H25N3O (383.199752)


C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent

   

CA 074 TFA

[L-3-trans-(Propylcarbamoyl)oxirane-2-carbonyl]-L-isoleucyl-L-proline

C18H29N3O6 (383.20562540000003)


D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015853 - Cysteine Proteinase Inhibitors D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents D020011 - Protective Agents

   

1-Piperidinecarboxylic acid, 3-hydroxy-4-[4-(phenylmethoxy)phenyl]-, 1,1-dimethylethyl ester, trans

1-Piperidinecarboxylic acid, 3-hydroxy-4-[4-(phenylmethoxy)phenyl]-, 1,1-dimethylethyl ester, trans

C23H29NO4 (383.20964740000005)


   

Anagliptin

Anagliptin

C19H25N7O2 (383.206963)


C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98086 - Dipeptidyl Peptidase-4 Inhibitor D007004 - Hypoglycemic Agents > D054873 - Dipeptidyl-Peptidase IV Inhibitors D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors C471 - Enzyme Inhibitor > C783 - Protease Inhibitor

   

(2R,4S)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid

(2R,4S)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid

C23H29NO4 (383.20964740000005)


   
   
   

(2S,4S)-5-([1,1-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)amino)-2-methylpentanoic acid

(2S,4S)-5-([1,1-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)amino)-2-methylpentanoic acid

C23H29NO4 (383.20964740000005)


   

(2S,4R)-5-([1,1-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)amino)-2-methylpentanoic acid

(2S,4R)-5-([1,1-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)amino)-2-methylpentanoic acid

C23H29NO4 (383.20964740000005)


   

2-(chloromethyl)oxirane; oxirane

2-(chloromethyl)oxirane; oxirane

C19H25N7O2 (383.206963)


   

9-(3-Methylphenyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-9H-carbazole

9-(3-Methylphenyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-9H-carbazole

C25H26BNO2 (383.2056486)


   

3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-9-(p-tolyl)-9H-carbazole

3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-9-(p-tolyl)-9H-carbazole

C25H26BNO2 (383.2056486)


   

Panicutine

Panicutine

C23H29NO4 (383.20964740000005)


A natural product found in Aconitum paniculatum and Delphinium denudatum.

   

3-(2-Hydroxy-4,6-dimethoxyphenyl)-1-(3-methyl-1-piperidinyl)-3-phenyl-1-propanone

3-(2-Hydroxy-4,6-dimethoxyphenyl)-1-(3-methyl-1-piperidinyl)-3-phenyl-1-propanone

C23H29NO4 (383.20964740000005)


   

N-({(2S)-1-[(3R)-3-Amino-4-(2-fluorophenyl)butanoyl]pyrrolidin-2-YL}methyl)benzamide

N-({(2S)-1-[(3R)-3-Amino-4-(2-fluorophenyl)butanoyl]pyrrolidin-2-YL}methyl)benzamide

C22H26FN3O2 (383.2008948)


   

Losmapimod

Losmapimod

C22H26FN3O2 (383.2008948)


C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2149 - Mitogen-Activated Protein Kinase Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

(1,4a-Dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-1-yl)methanamine;sulfuric acid

(1,4a-Dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-1-yl)methanamine;sulfuric acid

C20H33NO4S (383.2130178000001)


   

1-Octanoyl-2-hydroxy-sn-glycero-3-phosphocholine

1-Octanoyl-2-hydroxy-sn-glycero-3-phosphocholine

C16H34NO7P (383.2072784)


   

(3R)-1,2-didehydro-3-hydroxy-16-methoxy-2,3-dihydrotabersonine

(3R)-1,2-didehydro-3-hydroxy-16-methoxy-2,3-dihydrotabersonine

C22H27N2O4+ (383.19707220000004)


   

3-Epoxy-16-methoxy-2,3-dihydrotabersonine

3-Epoxy-16-methoxy-2,3-dihydrotabersonine

C22H27N2O4+ (383.19707220000004)


   
   

N-[2-[4-(dimethylamino)phenyl]-2-(1H-indol-3-yl)ethyl]benzamide

N-[2-[4-(dimethylamino)phenyl]-2-(1H-indol-3-yl)ethyl]benzamide

C25H25N3O (383.199752)


   

N-butyl-N-methyl-4-[(2-methyl-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)hydrazo]-4-oxobutanamide

N-butyl-N-methyl-4-[(2-methyl-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)hydrazo]-4-oxobutanamide

C19H25N7O2 (383.206963)


   

1-[[1-(4-Methoxyphenyl)-3-pyrrolidinyl]methyl]-3-(2,4,6-trimethylphenyl)thiourea

1-[[1-(4-Methoxyphenyl)-3-pyrrolidinyl]methyl]-3-(2,4,6-trimethylphenyl)thiourea

C22H29N3OS (383.20312240000004)


   

1-[(4-Methoxy-3-phenylmethoxyphenyl)methyl]-4-piperidinecarboxylic acid ethyl ester

1-[(4-Methoxy-3-phenylmethoxyphenyl)methyl]-4-piperidinecarboxylic acid ethyl ester

C23H29NO4 (383.20964740000005)


   

2-octanoyl-sn-glycero-3-phosphocholine

2-octanoyl-sn-glycero-3-phosphocholine

C16H34NO7P (383.2072784)


A 2-acyl-sn-glycero-3-phosphocholine in which the acyl group is specified as octanoyl.

   

(1R,5S)-7-[4-(3-methylphenyl)phenyl]-N-phenyl-3,6-diazabicyclo[3.1.1]heptane-3-carboxamide

(1R,5S)-7-[4-(3-methylphenyl)phenyl]-N-phenyl-3,6-diazabicyclo[3.1.1]heptane-3-carboxamide

C25H25N3O (383.199752)


   

1-[(1S,5R)-7-[4-(2-methylphenyl)phenyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]-2-pyridin-4-ylethanone

1-[(1S,5R)-7-[4-(2-methylphenyl)phenyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]-2-pyridin-4-ylethanone

C25H25N3O (383.199752)


   

(5S,6Z,8E,10E,12R,14Z)-5,12,20,20,20-pentahydroxyicosa-6,8,10,14-tetraenoate

(5S,6Z,8E,10E,12R,14Z)-5,12,20,20,20-pentahydroxyicosa-6,8,10,14-tetraenoate

C20H31O7- (383.2069676)


   

(E,8R)-8-[(2R,3R,5R,6S)-3-hydroxy-6-methyl-5-[(E)-2-methylbut-2-enoyl]oxyoxan-2-yl]oxynon-2-enoate

(E,8R)-8-[(2R,3R,5R,6S)-3-hydroxy-6-methyl-5-[(E)-2-methylbut-2-enoyl]oxyoxan-2-yl]oxynon-2-enoate

C20H31O7- (383.2069676)


   

N-[(2S)-2-hydroxy-2-(1,2,3,4-tetrahydronaphthalen-2-ylamino)ethyl]-6-(oxetan-3-ylamino)pyrimidine-4-carboxamide

N-[(2S)-2-hydroxy-2-(1,2,3,4-tetrahydronaphthalen-2-ylamino)ethyl]-6-(oxetan-3-ylamino)pyrimidine-4-carboxamide

C20H25N5O3 (383.19573)


   

[3-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] undecanoate

[3-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] undecanoate

C16H34NO7P (383.2072784)


   

[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-nonoxypropan-2-yl] acetate

[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-nonoxypropan-2-yl] acetate

C16H34NO7P (383.2072784)


   

[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-octoxypropan-2-yl] propanoate

[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-octoxypropan-2-yl] propanoate

C16H34NO7P (383.2072784)


   
   

1-octanoyl-sn-glycero-3-phosphocholine

1-octanoyl-sn-glycero-3-phosphocholine

C16H34NO7P (383.2072784)


   

(3R)-1,2-didehydro-3-hydroxy-16-methoxy-2,3-dihydrotabersoninium

(3R)-1,2-didehydro-3-hydroxy-16-methoxy-2,3-dihydrotabersoninium

C22H27N2O4 (383.19707220000004)


An indole alkaloid cation that is the conjugate acid of (3R)-1,2-didehydro-3-hydroxy-16-methoxy-2,3-dihydrotabersonine, obtained by protonation of the tertiary amino group. Major species at pH 7.3.

   
   
   
   

CC214-2

CC214-2

C20H25N5O3 (383.19573)


CC214-2 is an oral active and selective mTOR kinase inhibitor. CC214-2 targets to both of mTORC1 (pS6) and mTORC2 (pAktS473). CC214-2 induces autophagy, which is a potential target for host-directed therapy (HDT) in tuberculosis. CC214-2 exhibits synergistic bactericidal and sterilizing activity agasinst tuberculosis (TB), and shortens the treatment duration. CC214-2 also inhibits Rapamycin (HY-10219)-resistant signaling and the growth of glioblastomas in vitro and in vivo[1][2]. CC214-2 is an oral active and selective mTOR kinase inhibitor. CC214-2 targets to both of mTORC1 (pS6) and mTORC2 (pAktS473). CC214-2 induces autophagy, which is a potential target for host-directed therapy (HDT) in tuberculosis. CC214-2 exhibits synergistic bactericidal and sterilizing activity agasinst tuberculosis (TB), and shortens the treatment duration. CC214-2 also inhibits Rapamycin (HY-10219)-resistant signaling and the growth of glioblastomas in vitro and in vivo[1][2].

   

methyl 18-formyl-19-hydroxy-14-methyl-12-azahexacyclo[10.6.1.1¹,⁴.0¹⁰,¹⁸.0¹⁵,¹⁹.0⁷,²⁰]icosa-7(20),16-diene-3-carboxylate

methyl 18-formyl-19-hydroxy-14-methyl-12-azahexacyclo[10.6.1.1¹,⁴.0¹⁰,¹⁸.0¹⁵,¹⁹.0⁷,²⁰]icosa-7(20),16-diene-3-carboxylate

C23H29NO4 (383.20964740000005)


   

1-(2-hydroxy-1-methoxypropyl)-3-methoxy-2-methyl-6-(3-methylbut-2-en-1-yl)-9h-carbazol-4-ol

1-(2-hydroxy-1-methoxypropyl)-3-methoxy-2-methyl-6-(3-methylbut-2-en-1-yl)-9h-carbazol-4-ol

C23H29NO4 (383.20964740000005)


   

n-[2-(4-{[(2e)-3-(5,5-dimethyl-4-oxofuran-2-yl)but-2-en-1-yl]oxy}phenyl)ethyl]-3-methylbut-2-enimidic acid

n-[2-(4-{[(2e)-3-(5,5-dimethyl-4-oxofuran-2-yl)but-2-en-1-yl]oxy}phenyl)ethyl]-3-methylbut-2-enimidic acid

C23H29NO4 (383.20964740000005)


   

(1r,2s,3r,5r,10s)-17-(methoxycarbonyl)-2,6-dimethyl-20-oxo-8-azahexacyclo[11.5.1.1¹,⁵.0²,¹⁰.0³,⁸.0¹⁶,¹⁹]icosa-13(19),16-dien-8-ium-8-olate

(1r,2s,3r,5r,10s)-17-(methoxycarbonyl)-2,6-dimethyl-20-oxo-8-azahexacyclo[11.5.1.1¹,⁵.0²,¹⁰.0³,⁸.0¹⁶,¹⁹]icosa-13(19),16-dien-8-ium-8-olate

C23H29NO4 (383.20964740000005)


   

(3s,5r,8r,14s,18r)-5,7-dimethyl-12-methylidene-10,16-dioxo-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-yl acetate

(3s,5r,8r,14s,18r)-5,7-dimethyl-12-methylidene-10,16-dioxo-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-yl acetate

C23H29NO4 (383.20964740000005)


   

methyl (1r,3r,4r,10s,14s,15r,18r,19r)-18-formyl-19-hydroxy-14-methyl-12-azahexacyclo[10.6.1.1¹,⁴.0¹⁰,¹⁸.0¹⁵,¹⁹.0⁷,²⁰]icosa-7(20),16-diene-3-carboxylate

methyl (1r,3r,4r,10s,14s,15r,18r,19r)-18-formyl-19-hydroxy-14-methyl-12-azahexacyclo[10.6.1.1¹,⁴.0¹⁰,¹⁸.0¹⁵,¹⁹.0⁷,²⁰]icosa-7(20),16-diene-3-carboxylate

C23H29NO4 (383.20964740000005)


   

methyl (1r,2s,3r,5r,6s,10s)-2,6-dimethyl-21-oxo-14-oxa-8-azahexacyclo[11.6.1.1¹,⁵.0²,¹⁰.0³,⁸.0¹⁷,²⁰]henicosa-13(20),17-diene-18-carboxylate

methyl (1r,2s,3r,5r,6s,10s)-2,6-dimethyl-21-oxo-14-oxa-8-azahexacyclo[11.6.1.1¹,⁵.0²,¹⁰.0³,⁸.0¹⁷,²⁰]henicosa-13(20),17-diene-18-carboxylate

C23H29NO4 (383.20964740000005)


   

4-(hydroxymethyl)-7-methyl-8-[3-methyl-3-(3-methylpentyl)oxiran-2-yl]-9h-carbazole-1,6-diol

4-(hydroxymethyl)-7-methyl-8-[3-methyl-3-(3-methylpentyl)oxiran-2-yl]-9h-carbazole-1,6-diol

C23H29NO4 (383.20964740000005)


   

(3r,3as,9as)-9a-methyl-3-octanoyl-6-[(1e)-prop-1-en-1-yl]-3h,3ah,4h-furo[3,2-g]isoquinoline-2,9-dione

(3r,3as,9as)-9a-methyl-3-octanoyl-6-[(1e)-prop-1-en-1-yl]-3h,3ah,4h-furo[3,2-g]isoquinoline-2,9-dione

C23H29NO4 (383.20964740000005)


   

n-[2-(4-{[3-(5,5-dimethyl-4-oxofuran-2-yl)but-2-en-1-yl]oxy}phenyl)ethyl]-3-methylbut-2-enimidic acid

n-[2-(4-{[3-(5,5-dimethyl-4-oxofuran-2-yl)but-2-en-1-yl]oxy}phenyl)ethyl]-3-methylbut-2-enimidic acid

C23H29NO4 (383.20964740000005)


   

(1r,2s,3r,5r,6s,8r,10s)-17-(methoxycarbonyl)-2,6-dimethyl-20-oxo-8-azahexacyclo[11.5.1.1¹,⁵.0²,¹⁰.0³,⁸.0¹⁶,¹⁹]icosa-13(19),16-dien-8-ium-8-olate

(1r,2s,3r,5r,6s,8r,10s)-17-(methoxycarbonyl)-2,6-dimethyl-20-oxo-8-azahexacyclo[11.5.1.1¹,⁵.0²,¹⁰.0³,⁸.0¹⁶,¹⁹]icosa-13(19),16-dien-8-ium-8-olate

C23H29NO4 (383.20964740000005)


   

(1s,4r,5s,6s,9r,10r,13r)-6-hydroxy-5,9-dimethyl-12-oxo-14-azapentacyclo[11.7.1.0¹,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-15,17,19-triene-5-carboxylic acid

(1s,4r,5s,6s,9r,10r,13r)-6-hydroxy-5,9-dimethyl-12-oxo-14-azapentacyclo[11.7.1.0¹,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-15,17,19-triene-5-carboxylic acid

C23H29NO4 (383.20964740000005)


   

9a-methyl-3-octanoyl-6-(prop-1-en-1-yl)-3h,3ah,4h-furo[3,2-g]isoquinoline-2,9-dione

9a-methyl-3-octanoyl-6-(prop-1-en-1-yl)-3h,3ah,4h-furo[3,2-g]isoquinoline-2,9-dione

C23H29NO4 (383.20964740000005)


   

(1r,3s,5r,8r,9s,11s,14s,17r,18r)-5,7-dimethyl-12-methylidene-10,16-dioxo-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-yl acetate

(1r,3s,5r,8r,9s,11s,14s,17r,18r)-5,7-dimethyl-12-methylidene-10,16-dioxo-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-yl acetate

C23H29NO4 (383.20964740000005)


   

(12bs)-3,4,10,11-tetramethoxy-13,13-dimethyl-5,7,8,12b-tetrahydro-6-azatetraphene

(12bs)-3,4,10,11-tetramethoxy-13,13-dimethyl-5,7,8,12b-tetrahydro-6-azatetraphene

C23H29NO4 (383.20964740000005)


   

4,6-dihydroxy-2',5',5',8'a-tetramethyl-2',3,3',4',4'a,7',8,8'-octahydrospiro[furo[2,3-e]isoindole-2,1'-naphthalen]-6'-one

4,6-dihydroxy-2',5',5',8'a-tetramethyl-2',3,3',4',4'a,7',8,8'-octahydrospiro[furo[2,3-e]isoindole-2,1'-naphthalen]-6'-one

C23H29NO4 (383.20964740000005)


   

(1r,2s,3r,5r,6s,10s)-17-(methoxycarbonyl)-2,6-dimethyl-20-oxo-8-azahexacyclo[11.5.1.1¹,⁵.0²,¹⁰.0³,⁸.0¹⁶,¹⁹]icosa-13(19),16-dien-8-ium-8-olate

(1r,2s,3r,5r,6s,10s)-17-(methoxycarbonyl)-2,6-dimethyl-20-oxo-8-azahexacyclo[11.5.1.1¹,⁵.0²,¹⁰.0³,⁸.0¹⁶,¹⁹]icosa-13(19),16-dien-8-ium-8-olate

C23H29NO4 (383.20964740000005)


   

(2r,2'r,4'ar,8'as)-4,6-dihydroxy-2',5',5',8'a-tetramethyl-2',3,3',4',4'a,7',8,8'-octahydrospiro[furo[2,3-e]isoindole-2,1'-naphthalen]-6'-one

(2r,2'r,4'ar,8'as)-4,6-dihydroxy-2',5',5',8'a-tetramethyl-2',3,3',4',4'a,7',8,8'-octahydrospiro[furo[2,3-e]isoindole-2,1'-naphthalen]-6'-one

C23H29NO4 (383.20964740000005)


   

methyl (1s,2s,3s,5s,10r)-2,6-dimethyl-21-oxo-14-oxa-8-azahexacyclo[11.6.1.1¹,⁵.0²,¹⁰.0³,⁸.0¹⁷,²⁰]henicosa-13(20),17-diene-18-carboxylate

methyl (1s,2s,3s,5s,10r)-2,6-dimethyl-21-oxo-14-oxa-8-azahexacyclo[11.6.1.1¹,⁵.0²,¹⁰.0³,⁸.0¹⁷,²⁰]henicosa-13(20),17-diene-18-carboxylate

C23H29NO4 (383.20964740000005)